20190502 – TG-AZ agreement – ENG
Category: Invir.IO
Transgene and BioInvent Extend their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors
20190326 PR BioInvent extension CDR US
Antibody-armed oncolytic Vaccinia virus to block immunosuppressive pathways in the tumor microenvironment
Jean-Baptiste Marchand et al. SITC 2018, November 2018 – Abstract available on the SITC website Download the poster here Poster Presentation Collaboration between Transgene – BioInvent International A.B, Sweden
Transgene Highlights its Broad Viral Vector Expertise at the Society for Immunotherapy of Cancer (SITC) 2018 Conference
20181107 SITC Poster EN
Transgene and BioInvent present positive data at the SITC, supporting the co-development of a next-generation oncolytic virus encoding for an anti-CTLA-4 antibody
20181107 SITC Joint BioInvent Transgene EN
Transgene to Present its Viral Vector Expertise at the Society for Immunotherapy of Cancer Conference
20181001 SITC Poster VEN
BioInvent and Transgene collaborate on next generation oncolytic viruses encoding an anti-CTLA-4 antibody to treat solid tumors
BioInvent and Transgene collaborate on next generation oncolytic viruses encoding an anti-CTLA-4 antibody to treat solid tumors
Transgene and Randox Sign Collaboration to Develop Innovative Multifunctional Oncolytic Virotherapies for Solid Tumors
20171002-PR-TG-Randox-final
Transgene Launches Invir.IO™, its Integrated Platform for the Next Generation of Multifunctional Oncolytic Viruses
20170905 Invirio PR US
Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allow their intratumoral delivery and an improved tumor growth inhibition
Jean Baptiste Marchand, et al. XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016 Download the poster here Poster Presentation